Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-& alpha; therapy

作者全名："Luo, Haiying; Tan, Guili; Hu, Xiaoxia; Li, Yadi; Lei, Dingjia; Zeng, Yueying; Qin, Bo"

作者地址："[Luo, Haiying; Tan, Guili; Hu, Xiaoxia; Li, Yadi; Lei, Dingjia; Zeng, Yueying; Qin, Bo] Chongqing Med Univ, Dept Infect Dis, Chongqing Key Lab Infect Dis & Parasit Dis, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China; [Luo, Haiying; Hu, Xiaoxia] Chongqing Med Univ, Cent Lab, Affiliated Hosp 1, Chongqing, Peoples R China"

通信作者："Qin, B (通讯作者)，Chongqing Med Univ, Dept Infect Dis, Chongqing Key Lab Infect Dis & Parasit Dis, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China."

来源：VIROLOGY JOURNAL

ESI学科分类：MICROBIOLOGY

WOS号：WOS:001033795000001

JCR分区：Q2

影响因子：4

年份：2023

卷号：20

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：Hepatitis B virus; Chronic carriers; TRIM19; TRIM38; peg-IFN-& alpha;; Virological response

摘要："Objective To investigate whether the expression of triple motif protein 19/38 (TRIM19/38) mRNA in peripheral blood mononuclear cells (PBMCs) of HBeAg-negative chronic hepatitis B virus (HBV) carriers is associated with the response to pegylated interferon alpha (peg-IFN-a) treatment and HBsAg clearance.Methods In this prospective study, HBeAg-negative chronic HBV carriers treated with peg-IFN-a completed 48 weeks of follow-up. After treatment with peg-IFN-a, the patients were divided into responders (R group) and nonresponders (NR group) according to the changes in HBV DNA and HBsAg levels at week 48 of treatment. According to whether serum HBsAg loss or seroconversion occurred, the patients were divided into a serological response group (SR group) and a nonserological response group (NSR group). The level of TRIM19/38 mRNA in PBMCs was detected by real-time fluorescence quantitative PCR. The diagnostic performance of TRIM19/38 was analysed by calculating the receiver operating characteristic (ROC) curve and area under the ROC curve (AUC).Results 43 HBeAg-negative chronic HBV carriers, 35 untreated CHB patients and 19 healthy controls were enrolled in this study. We found that TRIM19/38 mRNA levels were significantly lower in untreated CHB patients than in healthy controls. In HBeAg-negative chronic HBV carriers who underwent prospective follow-up, TRIM19/38 mRNA levels were negatively correlated with HBV DNA and ALT at baseline. Among the patients treated with peg-IFN-a, 16 patients achieved a treatment response (R group) and 27 patients did not achieve a treatment response (NR group). Compared with baseline, HBsAg levels in the R group decreased significantly at 12 and 24 weeks of treatment; at the early stage of peg-IFN-a treatment, the dynamic changes in TRIM19/38 mRNA levels in the R and NR groups were different, and the TRIM19/38 mRNA levels in the R group were significantly higher than those in the NR group, especially at 24 weeks of treatment. ROC curve analysis showed that the changes in mRNA levels of TRIM19 and TRIM38 predicted the treatment response, with AUCs of 0.694 and 0.757, respectively. Among the patients treated with peg-IFN-a, 11 patients achieved a serological response (SR group) and 32 patients did not achieve a serological response (NSR group). Compared with baseline, HBsAg levels in the SR group decreased significantly at 12 and 24 weeks of treatment; TRIM19/38 mRNA levels were significantly higher in the SR group than in the NSR group at week 24.Conclusion The higher level of TRIM19/38 mRNA in PBMCs of HBeAg-negative chronic HBV carriers may be related to the early treatment effect of peg-IFN-a and HBsAg clearance. TRIM19 and TRIM38 have clinical significance in predicting virological response and guiding treatment regimens."

基金机构：Chongqing Natural Science Foundation of China [CSTC2020JCYJ-MSXMX0221]

基金资助正文：This study was supported by the General Project of the Chongqing Natural Science Foundation of China (CSTC2020JCYJ-MSXMX0221).